- AK1960, an ETA receptor antagonist, advances to Phase I trials for refractory diseases.
- Derived from Alchemedicine's HiSAP™ platform, AK1960 shows efficacy in animal models for kidney diseases.
- Asahi Kasei Pharma holds worldwide rights to develop and commercialize AK1960.
- Calliditas and Veloxis support AK1960's development for the global market.
Phase I Trial Initiation
Asahi Kasei Pharma, in collaboration with Alchemedicine, has advanced its novel Endothelin A (ETA) receptor antagonist, AK1960, into a Phase I clinical study. This follows a successful preclinical phase, marking a significant step in addressing refractory diseases, which are resistant to standard therapies.
AK1960 Development
AK1960 is a small molecule with a new core structure derived from Alchemedicine’s HiSAP™ platform. It exhibits high selectivity and potent inhibition for the ETA receptor, demonstrating efficacy in animal models for kidney diseases. The compound is expected to aid in treating difficult-to-control diseases, such as refractory chronic kidney diseases.
Global Collaboration
In 2022, Asahi Kasei Pharma and Alchemedicine entered an exclusive license agreement, granting Asahi Kasei Pharma worldwide rights to develop and commercialize the ETA receptor antagonist. While preclinical and Phase I studies are conducted in Japan, the program targets the global market. The development of AK1960 is supported by partnerships with Calliditas Therapeutics AB and Veloxis Pharmaceuticals, Inc.
Strategic Importance
The advancement of AK1960 into Phase I trials is a crucial milestone for Asahi Kasei Pharma, reflecting its commitment to addressing unmet medical needs. The company emphasizes value creation by advancing high-impact therapies globally, as outlined in its medium-term management plan. This initiative aligns with Asahi Kasei's strategy to enhance its healthcare sector and pharmaceutical R&D capabilities, aiming for long-term, sustainable growth.
